Opinion|Videos|November 29, 2024
The Role of BTK Inhibition in CSU
Key Takeaways
- BTK is crucial in mast cell degranulation, a process central to CSU pathophysiology.
- Inhibiting BTK can reduce histamine release, alleviating CSU symptoms.
Panelists discuss how Bruton tyrosine kinase’s (BTK) role in mediating mast cell degranulation makes it an ideal target for chronic spontaneous urticaria (CSU) treatment, as inhibiting BTK could effectively reduce histamine release and its associated symptoms.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- We previously discussed the role that BTK plays in mediating mast cell degranulation. Why does this make BTK an ideal target for CSU treatment?
Advertisement
Related to this article
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Asundexian Safely Reduces Ischemic Stroke Risk Regardless of Infarct Patterns on MRI
4
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
5